Clinical trials
HER2 Positive Solid Tumor clinical trials
Below are recruiting her2 positive solid tumor clinical trials, each written for real people, not researchers. We’re tracking 161 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06503783RecruitingPhase 1
Study of BL-M17D1 for advanced breast cancer and solid tumors
This trial tests a new drug, BL-M17D1, for people with advanced breast cancer (HER2 positive or negative) or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Harbin, HeilongjiangAges 18–75 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
La Jolla, CaliforniaAges 18 years+ - NCT06150885RecruitingPhase 1/Phase 2
An immune cell therapy for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR gamma-delta T cells) for advanced solid tumors that have not responded to standard treatments. The therapy uses donor cells that are specially trained to find and attack cancer cells.
Taichung, Non-USAges 18 years+ - NCT06120283RecruitingPhase 1
Study of BGB-43395 alone or with other drugs for advanced solid tumors
This study tests a new drug called BGB-43395 alone or with other treatments for advanced solid tumors, especially breast cancer. The goal is to find the best dose and see how well it works. It may be an option if your cancer has not responded to other treatments.
Denver, ColoradoAges 18 years+ - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT05957536RecruitingPhase 1
Testing a new drug for HER2-positive advanced solid cancers
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
Stanford, CaliforniaAges 18 years+ - NCT05868226RecruitingPhase 1/Phase 2
Personalized cancer treatment study for advanced solid tumors
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
Birmingham, AlabamaAges 18 years+ - NCT05673928RecruitingPhase 2
Tucatinib and T-DM1 for HER2-positive brain-metastasis tumors
This Phase 2 study tests tucatinib plus T-DM1 (ado-trastuzumab emtansine) in people with HER2-positive metastatic solid tumors that have spread to the brain. It aims to shrink brain and body tumors and help control cancer that is progressing in the brain.
Houston, TexasAges 18 years+ - NCT05631964RecruitingPhase 1
Early trial of BL-M07D1 for advanced HER2-positive digestive tumors
This early-phase trial tests BL-M07D1 in people with advanced digestive tract (and other solid) cancers that can’t be removed with surgery and have already tried or can’t use standard treatment. It’s studying whether the drug works and how safe it is, and whether HER2 tumor results are linked to benefit.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05584670RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This is an early (Phase 1/2) study of SAR445877, a new drug, in adults with advanced or metastatic solid cancers. It aims to find the safest dose and learn whether it can shrink tumors or help control disease when standard treatments aren’t available or no longer work.
Newark, DelawareAges 18 years+ - NCT05523947RecruitingPhase 1/Phase 2
Study drug for HER2-positive solid tumors, with dose changes
This early-stage study tests YH32367, a drug for people whose cancer is HER2-positive. It aims to find a safe dose and see whether it can shrink HER2-positive cancers that have spread or are hard to treat.
Boston, MassachusettsAges 18 years+ - NCT05461768RecruitingPhase 1
BL-M07D1 for HER2-positive or HER2-low breast cancer
This Phase 1 study tests BL-M07D1, a new investigational medicine, in people with HER2-positive or HER2-low breast cancer (and other solid tumors) that can’t be operated on or has spread. It aims to find a safe dose and learn how well the treatment may work based on HER2 levels in tumor tissue.
Fuzhou, FujianAges 18–75 - NCT05423977Enrolling by invitationPhase 1
Testing ZV0203 for HER2-positive advanced solid tumors
This Phase 1 study tests ZV0203, a new investigational treatment, in people with HER2-positive advanced or metastatic solid tumors that cannot be removed and have not responded to standard treatment. The goal is to find a safe dose and see how the disease responds.
Zigong, ShandongAges 18 years+ - NCT05315700RecruitingPhase 1/Phase 2
ORIC-114 for advanced lung or breast cancers with EGFR or HER2 changes
This early-phase study tests ORIC-114 to treat advanced solid tumors that have certain EGFR or HER2 genetic changes, often found in lung and breast cancers. It may help by targeting those specific cancer mutations, especially when standard treatments no longer work or aren’t tolerated.
Duarte, CaliforniaAges 18 years+ - NCT05245058RecruitingEarly Phase 1
SPH5030 for HER2-positive advanced solid tumors
This early-stage study tests SPH5030 tablets in people with HER2-positive advanced solid tumors that have not responded to standard treatment or have no standard option. It aims to see whether the treatment can shrink tumors and is safe enough to move forward.
Hefei, AnhuiAges 18 years+ - NCT05150691RecruitingPhase 1/Phase 2
Early study of an HER2 drug in advanced solid tumors
This early-phase trial tests DB-1303 and BNT323 together in people with advanced or metastatic solid cancers that have specific HER2 features. It may be an option when standard treatments have stopped working, aiming to find a safer dose and early signs of effectiveness.
Cerritos, CaliforniaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Birmingham, AlabamaAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Irvine, CaliforniaAges 12 years+ - NCT03740256RecruitingPhase 1
HER2-targeted oncolytic virus plus custom immune cells for solid cancers
This Phase 1 study tests a treatment plan that combines a virus designed to attack cancer with your own custom immune cells that target HER2. It aims to shrink advanced HER2-positive solid tumors (and make future options safer/more effective).
Houston, TexasAges 18 years+ - NCT05979155RecruitingPhase 1
Study of NWY001 for advanced solid tumors
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Guangzhou, GuangdongAges 18–75 - NCT07512583RecruitingPhase 1/Phase 2
TQB2930 injection for advanced solid tumors with HER2 expression
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07436728RecruitingPhase 1/Phase 2
Study of TAK-505 for adults with solid tumors
This trial tests TAK-505, an experimental drug, for people with advanced solid tumors including lung, colorectal, stomach, or head and neck cancers. It aims to see if the drug can help when standard treatments are no longer working or aren't suitable.
Orange, CaliforniaAges 18 years+
Hear when a new HER2 Positive Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive solid tumor?
- Yes. Clin2 currently lists 161 recruiting her2 positive solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.